Brief: Synthaverse Says CoraPharm Gets Marketing Authorization For Onko BCG In Bosnia and Herzegovina
05/06/2025 06:28
June 5 (Reuters) - Synthaverse SA SVEP.WA: SAID ON WEDNESDAY THAT CORAPHARM OBTAINED MARKETING AUTHORIZATION FOR ONKO BCG IN BOSNIA AND HERZEGOVINA COMPANY EXPECTS ONKO BCG MARKET AUTHORIZATION IN SERBIA IN Q4 2025 Source text for Workspace: nEM4qzsHca Further company coverage: SVEP.WA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Synthaverse SA
See all newsBrief: Synthaverse EGM To Vote On Share Capital Increase Via Series X Share Issue
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility